SOURCE: Curidium Medica PLC

January 23, 2008 02:02 ET

Curidium Medica PLC announces Change of Adviser

London--(Marketwire - January 23, 2008) -

                              Curidium Medica plc

                         ("Curidium" or "the Company")


                               CHANGE OF ADVISER


LONDON, UK, 23 January 2008, Curidium Medica plc, (LSE:CUR), the personalized
medicine company focused on bringing the right drug to the right patient,
announced today the appointment of JMFinn Capital Markets as nominated adviser
and broker, with immediate effect.

Gosse B. Bruinsma, M.D., Executive Chairman, said "The appointment of JMFinn
Capital Markets is a major step forward for Curidium and we are pleased to have
them as our partners in further increasing awareness of Curidium Medica among
investors."


Ends


For further information please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Charlie Cunningham +44 (0) 20 7600 1658
JM Finn Capital Markets Ltd

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics


Notes to Editors


Curidium Medica plc (Curidium)

Curidium is a personalized medicine company developing companion diagnostics and
targeted medicines to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted
in the identification of a blood diagnostic test, PsychINDxTM, which classifies
patients with schizophrenia/bipolar disorder into four subgroups. PsychINDxTM
may have the potential to improve the treatment of patients with schizophrenia/
bipolar disorder.


Many chronic human diseases are heterogeneous with patient populations
consisting of mixed subgroups. Through the use of its proprietary analysis tool,
Homomatrix(R), Curidium aims to reveal different patient subgroups characterized
by distinct underlying disease mechanisms potentially leading to the
identification of:

 1. Diagnostics for better identification and treatment within heterogeneous
    disease populations.
 2. Improved therapies identified through novel drug targets.
 3. Personalized medicines using companion diagnostics and targeted treatments.


Curidium intends to continue to use this approach to improve patient treatments
in a variety of therapeutic areas. Further information on Curidium can be found
at the Company's website: www.curidium.com.


Curidium Medica plc (c) 2002-2008. All rights reserved.

Studio 10, Tiger House, London WC1H 9BY, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791







                      This information is provided by RNS
            The company news service from the London Stock Exchange